Galsky MD - Search Results

1

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.

Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK. Martini A, et al. Among authors: galsky md. Prostate Cancer Prostatic Dis. 2021 Sep;24(3):743-749. doi: 10.1038/s41391-021-00326-3. Epub 2021 Feb 2. Prostate Cancer Prostatic Dis. 2021. PMID: 33531652

2

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Galsky MD, et al. J Clin Oncol. 2005 Mar 1;23(7):1439-46. doi: 10.1200/JCO.2005.09.042. J Clin Oncol. 2005. PMID: 15735119 Clinical Trial.

3

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Among authors: galsky md. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

4

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sonpavde G, et al. Among authors: galsky md. Ann Oncol. 2010 Feb;21(2):319-324. doi: 10.1093/annonc/mdp323. Epub 2009 Jul 24. Ann Oncol. 2010. PMID: 19633050 Free article. Clinical Trial.

5

Docetaxel-based combination therapy for castration-resistant prostate cancer.

Galsky MD, Vogelzang NJ. Galsky MD, et al. Ann Oncol. 2010 Nov;21(11):2135-2144. doi: 10.1093/annonc/mdq050. Epub 2010 Mar 29. Ann Oncol. 2010. PMID: 20351071 Free article. Review.

6

Cabazitaxel.

Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Galsky MD, et al. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. Nat Rev Drug Discov. 2010. PMID: 20811375 No abstract available.

7

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. Galsky MD, et al. Lancet Oncol. 2011 Mar;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8. Lancet Oncol. 2011. PMID: 21376284 No abstract available.

8

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Galsky MD, et al. Ann Oncol. 2012 Feb;23(2):406-10. doi: 10.1093/annonc/mdr156. Epub 2011 May 4. Ann Oncol. 2012. PMID: 21543626 Free article.

9

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Galsky MD, et al. J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555688 Review.

10

Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

Tsao CK, Seng S, Oh WK, Galsky MD. Tsao CK, et al. Among authors: galsky md. Clin Med Insights Oncol. 2011;5:163-9. doi: 10.4137/CMO.S6566. Epub 2011 May 24. Clin Med Insights Oncol. 2011. PMID: 21695098 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

407 results

Search Page